Abstract Background and Aims: There is growing evidence that in Crohn's disease the
achievement and maintenance of mucosal healing (MH) through anti-TNFα antibodies may …

Purpose The anti-tumor necrosis factor (TNF) agents infliximab (IFX) and adalimumab (ADA)
have been recently introduced to treat severe inflammatory bowel disease (IBD) that is …

Objective To assess the clinical efficacy and the impact of infliximab (IFX) induction therapy
on mucosal healing in Polish children with Crohn's disease (CD). Methods A total of 66 …

Objectives: We aimed to identify early noninvasive predictors of clinical and endoscopic
remission in children with Crohn disease (CD) under infliximab (IFX). Methods: Prospective …

Abstract Background and Aims: We aimed to compare the efficacy of combined
immunosuppression in terms of mucosal healing in paediatric patients with moderate-to …

Abstract Objective. Pediatric Crohn's disease (CD) is often debilitating, with upper
gastrointestinal (GI) involvement and complications over time. Treatment with tumor necrosis …

Objective: The antitumor necrosis factor α (TNFα) antibodies infliximab and adalimumab are
effective in inducing and maintaining remission in pediatric patients with Crohn disease …

Abstract Background and Aims Mucosal healing is an important treatment goal in Crohn's
disease. We investigated the association between serum infliximab trough levels and …

Aim: To assess the usefulness of intestinal healing phenomenon in CD, defined as
improvement both in endoscopy and MRE, after anti-TNF induction therapy, in predicting …

WJS Research has shown that tumor necrosis factor (TNF) is overexpressed in patients with
moderate-tosevere ulcerative colitis (UC); this proinflammatory cytokine can be measured in …